Skip navigation | ||
|
||
Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
|
|
|
Alternative Names Return to top
Anthrax - inhalationDefinition Return to top
Inhalation (or respiratory) anthrax is an infectious disease caused by breathing in the spores of the bacteria Bacillus anthracis.
Causes Return to top
Anthrax commonly affects hoofed animals such as sheep and goats, but humans can get sick from anthrax, too. Historically, the main risk factor for getting anthrax was some type of contact with contaminated animal hides, hair, bone products, and wool. Inhalation anthrax was most commonly contracted when workers breathed in airborne anthrax spores, which were released during industrial processes such as tanning hides and processing wool.
Breathing in spores means a person has been exposed to the disease, but it doesn't mean they'll get symptoms. The bacteria spores must "germinate," or sprout ( the same way a seed might before a flower grows) before the actual disease occurs. The process can take up to 60 days.
Once the spores germinate, they release several toxic substances, which cause internal bleeding, swelling, and tissue death.
The main form of inhalational anthrax is a bloody infection of the lymph nodes in the chest, a condition called hemorrhagic mediastinitis. Up to half of affected individuals may also have a hemorrhagic meningitis.
Symptoms Return to top
There are usually two stages of inhalation anthrax:
This list of symptoms is based on a relatively small number of people who have had inhalation anthrax. Additional symptoms may occur.
Exams and Tests Return to top
Tests may include:
Initial chest x-rays are likely to show abnormalities such as fluid surrounding the lungs or abnormally wide space between the lungs.
Fluid or blood samples may need to be sent to a lab for more specialized testing.
A spinal tap for CSF culture and a gram stain also may be performed.
Treatment Return to top
Several antibiotics are effective against anthrax, including penicillin, doxycycline, and ciprofloxacin. Inhalation anthrax is usually treated with ciprofloxacin plus another antibiotic agent.
The length of treatment is currently about 60 days for individuals exposed to anthrax, since it may take spores that long to germinate.
Outlook (Prognosis) Return to top
The prognosis of inhalation anthrax once it reaches the second stage is poor, even with antibiotic therapy. Up to 90% of cases in the second stage are fatal.
Possible Complications Return to top
When to Contact a Medical Professional Return to top
Notify your health care provider if you have been exposed to anthrax, whether or not you develop symptoms.
Prevention Return to top
An anthrax vaccine is available to select U.S. military personnel, but not the general public.
For individuals who have been truly exposed to anthrax (but have no signs and symptoms of the disease), preventive antibiotics may be offered.
Anthrax is not known to spread from person to person.People living with individuals with anthrax do not need antibiotics unless they have also been exposed to the same source of anthrax.
References Return to top
Reissman DB, Whitney EA, Taylor TH Jr, et al. One-Year Health Assessment of Adult Survivors of Bacillus anthracis Infection.JAMA. 2004;291:1994-1998.
Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a Biological Weapon, 2002. JAMA.160;2002;287:2236-2252.
Update Date: 6/29/2007 Updated by: Cyrus Badshah, MD, PhD, Assistant Professor of Clinical Medicine, College of Physicians and Surgeons, Columbia University; Assistant Attending Physician, Department of Medicine, Division of Infectious Diseases & Medical Director, Chest (TB) Clinic and Directly Observed Therapy Program, Harlem Hospital Center. Review provided by VeriMed Healthcare Network.
Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 29 January 2009 |